Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis

• Published in: Obesity science & practice 2024-04, Vol.10 (2), p.e743-n/a
• Main Authors: Dutta, Deep, Nagendra, Lakshmi, Anne, Beatrice, Kumar, Manoj, Sharma, Meha, Kamrul‐Hasan, A. B. M.
• Format: Article
• Language: English
• Subjects: Agonists; Bias; Blood pressure; Body mass index; Body weight loss; Clinical trials; Constipation; Diabetes; Diabetes mellitus; Drug dosages; emerging treatments; Gastroesophageal reflux; GLP1RA; Glucagon; Glucagon-like peptide 1; Hemoglobin; medications; Medicine; Meta-analysis; Obesity; orforglipron; Peptides; Placebos; Review; Side effects; Systematic review; Weight control
• ISSN: 2055-2238; 2055-2238
• DOI: 10.1002/osp4.743

Background Orforglipron is a novel once‐daily oral non‐peptide glucagon‐like peptide‐1 receptor agonist with several recently published randomized controlled trials (RCTs) evaluating its role in diabetes and obesity. No meta‐analysis has analyzed the efficacy and safety of orforglipron; this meta‐analysis aimed to address this knowledge gap. Methods A systematic search was conducted in electronic databases to identify RCTs that included individuals with obesity who were administered orforglipron and compared to either a placebo or an active comparator. The primary outcome of interest was the percent change in body weight. Results From 12 initially screened articles, data from three RCTs involving 774 people were analyzed with a follow‐up duration of up to 36 weeks. Compared to placebo, patients receiving orforglipron 12 mg/day (mean difference (MD), MD −5.48%, 95% CI [−7.64, −3.33], p